Futility approaches to interim monitoring by data monitoring committees

Clinical Trials

Volumn 3, Issue 6, 2006, Pages 522-529

  DeMets, David L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIALS DATA MONITORING COMMITTEES; DECISION MAKING; HUMANS; MEDICAL FUTILITY; PROBABILITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS;

EID: 49749131610     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774506073115     Document Type: Conference Paper

References (32)

1. US Food and Drug Administration. Draft guidance for clinical trial sponsors on the establishment and operation of Clinical Trial Data Monitoring Committees. Rockville, MD: FDA (http://www.fda.gov/cber/gdlns/ clindatmon.htm), 2001.
2. Committee for Medicinal Products for Human Use (CHMP) Guidelines. Guidelines on Data Monitoring Committees, European Medicine Agency, July 2005.
3. National Institutes of Health. NIH policy for data and safety monitoring. NIH Guide (http://grants2.nih.gov/grants/guide/notice-files/ not98-084.html), 1998.
4. Ellenberg S, Fleming T, DeMets D. Data monitoring committees in clinical trials: A practical perspective. John Wiley & Sons, Ltd., 2002.
5. Greenberg Report. Organization, review, and administration of cooperative studies. Control Clin Trials 1988; 9: 137-148.
6. Shalala D. Protecting research subjects - what must be done. New Engl J Med 2000; 343: 808-810.
7. Psaty BM, Furberg CD. COX-2 inhibitors - lessons in drug safety. New Engl J Med 2005; 325: 1133-1135.
8. Armitage P, McPherson CK, and Rowe BC. Repeated significance tests on accumulating data. Journal of the Royal Statistical Society Series A 1969; 132: 235-244.
9. Canner PL, Klimt CR. Experimental design features of the Coronary Drug Project. Control Clin Trials 1983; 4: 313-332.
10. DeMets DL, Lan KKG. Interim analysis: The alpha spending function approach. Stat in Med 1994; 13: 1341-1352.
11. Jennison C, Turnbull BW. Statistical approaches to interim monitoring of medical trials: A review and commentary. Statistical Science 1990; 5: 299-317.
12. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556.
13. DeMets DL, Pocock S, Julian DG. The agonizing negative trend in monitoring clinical trials. Lancet 1999; 354: 1983-1988.
14. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Result of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med 1987; 316: 1429-1435.
15. Budaj A, Herbaczynska-Cedro K, Kokot F et al. Effect of early captopril treatment on blood adrenaline levels in acute myocardial infarction (the substudy of ISIS-4). International Study of Infarct Survival-4. Amer J of Cardiol 1998; 81: 335-339.
16. Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475.
17. Feldman AM, Bristow MR, Parmley WW et al. for The Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. New Engl J Med 1993; 329: 149-155.
18. Cohn J, Goldstein S, Greenberg B et al. for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. New Engl J Med 1998; 339: 1810-1816.
19. Grady D, Applegate W, Bush T et al. Heart and estrogen/progestin replacement study (HERS): Design, methods, and baseline characteri-stics. Control Clin Trials 1998; 19: 314-335.
20. Writing Group for the Women' s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women' s Health Initiative Randomized Clinical Trial. JAMA 2002; 288: 321-333.
21. The Women' s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women' s Health Initiative Randomized Controlled Trial. JAMA 2004; 291: 1701-1712.
22. Hulley SB, Grady D. The WHI estrogen-alone trial-things look any better? Editorial. JAMA 2004; 291: 1769-1771.
23. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-381.
24. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663.
25. Emerson SS, Fleming TR. Symmetric group sequential test designs. Biometrics 1989; 45: 905-932.
26. Tsiatis AA, Rosner GL, Mehta CR. Exact confidence intervals following a group sequential test. Biometrics 1984; 40: 797-803.
27. Whitehead J, Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics 1983; 39: 227-236.
28. Whitehead J. A unified theory for sequential clinical trials. Stat Med 1999; 18: 2271-2286.
29. Lan KKG, Wittes J. The B-value: A tool for monitoring data. Biometrics 1988; 44: 579-585.
30. Lan KKG, Zucker D. Sequential monitoring of clinical trials: The role of information in Brownian motion. Stat Med 1993; 12: 753-765.
31. Spiegelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials: conditional or predictive power? Control Clin Trials 1986; 7: 8-17.
32. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. J Royal Statist Soc A 1994; 157: 357-416.